Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - targeted+therapy
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
A Novel “Host-Guest”-Based Supramolecular Hydrogel for Dental Pulp Regeneration (Case No. 2023-154)
Summary: Researchers in the Department of Dentistry at UCLA have developed an innovative hydrogel for a vast array of biomedical and tissue engineering applications. Background: Hydrogels have emerged as powerful tools in biomedical engineering due to their ability to provide a supportive environment for cell growth, tissue repair, and drug delivery....
Published: 10/14/2024
|
Inventor(s):
Alireza Moshaverinia
,
Weihao Yuan
Keywords(s):
anti-dehydration
,
Drug Delivery
,
dynamic identification
,
hydrogel
,
Stem Cells / Regenerative Medicine
,
Targeted Therapy
,
tissue regeneration
Category(s):
Chemical
,
Materials > Functional Materials
,
Platforms > Drug Delivery
,
Platforms > Drug Delivery > Antibody Delivery Platforms
,
Platforms > Drug Delivery > Nanoparticles
,
Platforms > Drug Delivery > Viral Delivery Systems
,
Therapeutics > Cell Therapy
,
Therapeutics > Medication
,
Therapeutics > Stem Cells And Regenerative Medicine
IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)
Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. The...
Published: 4/8/2024
|
Inventor(s):
Scott Durum
,
Julie Hixon
,
Wenqing Li
,
Scotch Walsh
,
Lila Kashi
Keywords(s):
Acute lymphoblastic leukemia (ALL)
,
ANTIBODY
,
Antibody-Dependent Cellular Cytotoxicity (ADCC)
,
Autoimmunity
,
CANCER
,
DIABETES
,
Durum
,
Interleukin-7 receptor-α (IL-7Rα)
,
Multiple sclerosis
,
personalized medicine
,
Targeted therapy
,
THERAPY
,
TRANSPLANTATION
Category(s):
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Oncology
,
Collaboration Sought > Collaboration
Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors
Abstract: This invention describes a general way to trigger the release of a bioactive small molecule from a targeting antibody. The key “trigger” is a fluorescent linker that is chemically disassembled upon irradiation with light in the near-IR range (~800 nm). This linker technology is a dramatic step forward for the field. The molecules can be tracked...
Published: 4/8/2024
|
Inventor(s):
Martin Schnermann
,
Alexander Gorka
,
Hisataka Kobayashi
,
Roger Nani
Keywords(s):
ADC
,
Antibody-drug Conjugate
,
Chemical linkers
,
Fluorescent linker
,
PDT
,
personalized medicine
,
Photodynamic therapy
,
Targeted drug release
,
Targeted therapy
Category(s):
TherapeuticArea > Oncology
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Therapeutics
A Novel Device to Produce Autologous Serum Eye Drops at the Point of Care (Case No. 2021-198)
SUMMARY: UCLA researchers in the Stein and Doheny Eye Institutes have designed a device that can produce autologous serum eye drops at the point-of-care, greatly reducing the cost and complexity of the production process. BACKGROUND: Ocular surface diseases afflict hundreds of millions of people per year worldwide. Autologous serum eye drops benefit...
Published: 9/29/2023
|
Inventor(s):
Justin Karlin
Keywords(s):
Human Serum Albumin
,
Medical Devices and Materials
,
Targeted Therapy
,
Therapeutics & Vaccines
Category(s):
Life Science Research Tools > Lab Equipment
,
Therapeutics > Ophthalmology